Ropivacaine
Clinical data | |
---|---|
Trade names | Naropin, Rocaine |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Parenteral | |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 87%–98% (epidural) |
Metabolism | Liver (CYP1A2-mediated) |
Elimination half-life | 1.6–6 hours (varies with administration route) |
Excretion | Kidney 86% |
Identifiers | |
| |
JSmol) | |
Melting point | 144 to 146 °C (291 to 295 °F) |
| |
| |
(verify) |
Ropivacaine (
racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca
under the brand name Naropin.
History
Ropivacaine was developed after bupivacaine was noted to be associated with cardiac arrest, particularly in pregnant women. Ropivacaine was found to have less cardiotoxicity than bupivacaine in animal models.
Clinical use
Contraindications
Ropivacaine is contraindicated for
intravenous regional anaesthesia (IVRA). However, new data suggested both ropivacaine (1.2-1.8 mg/kg in 40ml) and levobupivacaine (40 ml of 0.125% solution) can be used, because they have less cardiovascular and central nervous system toxicity than racemic bupivacaine.[1]
Adverse effects
Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.
Systemic exposure to excessive quantities of ropivacaine mainly result in
hypoxemia secondary to respiratory depression.[2]
Postarthroscopic glenohumeral chondrolysis
Ropivacaine is toxic to cartilage and their intra-articular infusions can lead to Postarthroscopic glenohumeral chondrolysis.[3]
Treatment of overdose
As for
References
External links
- "Ropivacaine". Drug Information Portal. U.S. National Library of Medicine.
- "Ropivacaine hydrochloride". Drug Information Portal. U.S. National Library of Medicine.